Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...

Field Medical announced today that it received FDA breakthrough device designation for its FieldForce pulsed field ablation ...

GREENVILLE, N.C. (WITN) -Flu season is underway and the weather is getting colder. As many prepare to see friends and family this holiday season, the Centers for Disease Control and Prevention ...

Medtech executives expect the technology to help fuel their companies’ future growth. Boston Scientific CEO Mike Mahoney has ...

BSX’s outperformance over the past year can be primarily attributed to its differentiated portfolio, strategic acquisitions like Farapulse, its category leadership strategy, and robust ...

Valued at a market cap of $133.6 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets medical ...

Dr. Robert Ward prepares part of the FARAPULSE Pulsed Field Ablation System for a pulsed field ablation procedure to treat a patient with atrial fibrillation at Mayo Clinic Hospital, Saint Marys ...